Departments of Family Medicine and Public Health, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
Diabetes Care. 2013 Mar;36(3):591-7. doi: 10.2337/dc12-0755. Epub 2012 Nov 12.
To investigate temporal improvements in blood pressure (BP) control in subjects with diabetes and policy changes regarding generic antihypertensives.
In a cross-sectional study we used logistic regression models to investigate the temporal relationship between access to generic antihypertensive medications and BP control (<130/80 mmHg) in 5,375 subjects (mean age, 66 ± 9 years; 61% African American) with diabetes and hypertension (HTN) enrolled in the national Results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study between 2003 and 2007. At enrollment, BP was measured and medications in the home determined by medication label review by a trained professional. Generic antihypertensive medication status was ascertained from the U.S. Food and Drug Administration.
The percentage of subjects accessing generically available antihypertensive medications increased significantly from 66% in 2003 to 81% in 2007 (P < 0.0001), and the odds of achieving a BP <130/80 mmHg in 2007 was 66% higher (odds ratio 1.66 [95% CI 1.30-2.10]) than in 2003. Nevertheless, <50% of participants achieved this goal. African American race, male sex, limited income, and medication nonadherence were significant predictors of inadequate BP control. There was no significant relationship between access to generic antihypertensives and BP control when other demographic factors were included in the model (0.98 [0.96-1.00]).
Among African American and white subjects with HTN and diabetes, BP control remained inadequate relative to published guidelines, and racial disparities persisted. Although access to generic antihypertensives increased, this was not independently associated with improved BP control, suggesting that poor BP control is multifactorial.
研究糖尿病患者的血压(BP)控制在药物可及性和通用降压药物政策改变方面的时间改善情况。
在一项横断面研究中,我们使用逻辑回归模型,研究了在 5375 名患有糖尿病和高血压(HTN)的受试者中(平均年龄 66±9 岁,61%为非裔美国人),自 2003 年至 2007 年,进入国家原因地理和种族差异中风(REGARDS)队列研究时,可获得通用降压药物与 BP 控制(<130/80mmHg)之间的时间关系。在入组时,通过经过培训的专业人员进行药物标签审查,测量血压并确定家中的药物。通用降压药物的使用情况通过美国食品药品监督管理局(U.S. Food and Drug Administration)确定。
从 2003 年的 66%到 2007 年的 81%,可获得通用降压药物的患者比例显著增加(P<0.0001),2007 年达到 BP<130/80mmHg 的可能性比 2003 年高 66%(优势比 1.66[95%CI 1.30-2.10])。尽管如此,仍<50%的患者达到了这一目标。非裔美国人种族、男性、收入有限和药物依从性差是 BP 控制不佳的显著预测因素。当将其他人口统计学因素纳入模型时,通用降压药物的可及性与 BP 控制之间没有显著关系(0.98[0.96-1.00])。
在患有 HTN 和糖尿病的非裔美国人和白人患者中,BP 控制仍不符合已发布的指南,且种族差异持续存在。尽管可获得通用降压药物的机会增加,但这与改善 BP 控制无关,这表明 BP 控制不佳是多因素的。